SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Ann Richards

PatientAnn Richards
Date of birth1962-09-01
IdentifiersMRN HR-ML019-SYN; SSN (made up) 000-19-3381
Document date2026-08-11
AuthorRosalind Teague, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month bone health review, three months after the first zoledronic acid infusion. [S]

History of Present Illness

Ms. Richards returns three months after her first zoledronic acid infusion. The evening after the infusion she had aching muscles and a temperature of 37.9 °C, which settled with acetaminophen and were gone on the third day; she has had no symptoms since. She has had no muscle cramps, tingling, jaw pain, or thigh or groin pain. She takes vitamin D3 2000 units a day and keeps her calcium at about 1200 mg a day from food. She does the home balance program three times a week, walks most days, and has had no falls. She came fasting this morning for her blood tests. She has had no alcohol. [S]

ElementDetail
Infusion reactionAches and 37.9 °C for two days after the dose, settled with acetaminophen
Drug safetyNo cramps, tingling, jaw pain, or thigh or groin pain
Supplements and dietD3 2000 units daily; calcium about 1200 mg a day from food
FallsNone; home balance program three times a week
RecoveryNo alcohol; no cravings

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or fatigue since the third day after the infusion
MusculoskeletalNegativeNo bone, thigh, or groin pain; no muscle cramps
Ears, nose, mouth, and throatNegativeNo jaw pain, loose teeth, or mouth sores
EyesNegativeNo eye pain or redness
PsychiatricNegativeMood good; no cravings; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet dailyOne tablet by mouth dailyOral route2026-02-10activeS
Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 monthsOnce every 12 months, given in the clinic infusion room after a calcium and creatinine checkIntravenous route2026-05-12activeS
Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day)Two tablets every 6 hours as needed for up to three days after the infusionOral route2026-05-12 to 2026-05-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-11Body height164cmS
2026-08-11Body weight66kgS
2026-08-11Body mass index (BMI) [Ratio]24.5kg/m2S
2026-08-11Systolic blood pressure122mm[Hg]S
2026-08-11Diastolic blood pressure76mm[Hg]S
2026-08-11Heart rate68/minS
2026-08-11Respiratory rate14/minS
2026-08-11Body temperature36.7CelS
2026-08-11Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-11Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma190pg/mLPostmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates responseNormalS
2026-08-11Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 66.0 kg
MouthNo exposed bone or gum swelling
MusculoskeletalNo thigh tenderness; full painless hip movement
Gait and balanceTimed Up and Go 9 seconds; tandem stance 20 seconds

Problems

ProblemClinical statusVerificationCodeProvenance
Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold)activeconfirmed M85.89S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture.
Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol sinceactiveconfirmed F10.21S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit.
History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls sinceactiveconfirmed Z91.81S — Synthetic modern entry linked to her publicly described falls and fractures.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBone-turnover marker (fasting serum CTX)Baseline, then 3 to 6 months after starting or changing therapyCompleted today190 pg/mL, 66 percent below the baseline of 560; response and adherence confirmed
LaboratorySerum calciumBefore each zoledronic acid dose, and after the first dose if symptoms suggest hypocalcemiaCompleted today9.3 mg/dL, normal; checked with the CTX sample
Laboratory25-hydroxyvitamin DAfter repletion until 30 ng/mL or more; then yearlyUp to date38 ng/mL in May; next with the pre-infusion tests in May
Medication safetyAcute-phase reaction after zoledronic acidAfter the first doseCompleted todayAches and 37.9 °C for two days, settled with acetaminophen; acetaminophen offered again for the next dose
Medication safetyOsteonecrosis of the jaw and atypical femoral fracture symptomsAt each visit on antiresorptive therapyCompleted todayNo jaw pain or exposed bone; no thigh or groin pain; routine dental care twice a year
ImagingCentral DXA of the spine and hipEvery 1 to 2 years on therapy until stable, on the same scannerUp to dateDue two years after starting therapy, on the same scanner
ExaminationStanding height by stadiometerYearly; vertebral imaging again if height falls 2 cm or moreUp to date164.0 cm, unchanged
ExaminationFall-risk screenYearly, and with any fallCompleted todayTimed Up and Go 9 seconds, tandem stance 20 seconds; no falls
SurveyFRAX 10-year fracture riskAt baseline, when risk factors change, and at the drug-holiday decisionUp to dateNo change in risk factors; next at the drug-holiday decision
SurveyCalcium intake assessmentAt baseline and yearlyUp to dateAbout 1200 mg a day from food
Medication safetyDrug-holiday eligibilityAfter 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonateNot indicatedOne dose so far; reassess after the third yearly dose
Self-managementBalance and strength exercise programWith a history of falls or impaired balanceUp to dateHome program three times a week
Self-managementRecovery check (alcohol, cravings, stress)Every visitCompleted todayNo alcohol; no cravings
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Adult preventive visit in October. Second zoledronic acid dose in May with pre-infusion tests. Call for jaw pain, thigh or groin pain, or any fall. Next scheduled visit 2026-10-06: adult preventive visit. [S]